Scholar Rock Holding Executive Compensation (FY25)
SRRK · Executive and director compensation, fiscal 2024 to 2025
The Scholar Rock Holding brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Data as of September 7, 2026Latest filing (8-K): June 5, 2026
6 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
$1,500Get the executive brief
141 figures on this page: 138 cited to the filing that reported them, 3 calculated from figures it prints. See the citations
This company is not required to report a chief executive pay ratio.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive of record: Jay Backstrom → David Hallal
Say-on-pay support: 96.3% → 61.7% (34.6 points lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is Scholar Rock Holding's chief executive and what were they paid?
David Hallal was paid $33,300,927 in total compensation as Chief Executive Officer and Chairman for fiscal 2025.
What was Scholar Rock Holding's say-on-pay result?
Shareholders supported the say-on-pay proposal with 61.7% of votes cast for or against in favor at the meeting held June 4, 2026 for fiscal 2025.
Which companies are in Scholar Rock Holding's peer group?
The disclosed peer group names Agios Pharmaceuticals, Inc., Apellis Pharmaceuticals, Inc., Arcus Biosciences, Inc., Arrowhead Pharmaceuticals, Inc. and Avidity Biosciences, Inc., among others.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Jay Backstrom Former President and Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
David Hallal Chief Executive Officer and Chairman | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Jay Backstrom Former President and Chief Executive Officer Departed during or after this year | ◇ | — | ◇ | ◇ | — | — | ◇ | ◇ |
Akshay Vaishnaw President of R&D | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
R. Keith Woods Chief Operating Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Vikas Sinha Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Akshay Vaishnaw | PRSU | — | — | — | — | — | — | ◇ |
| Akshay Vaishnaw | Option | — | — | — | — | — | — | ◇ |
| David Hallal | PRSU | — | — | — | — | — | — | ◇ |
| David Hallal | Option | — | — | — | — | — | — | ◇ |
| Jay Backstrom | Option | — | — | — | — | — | — | ◇ |
| Jay Backstrom | PRSU | — | — | — | — | — | — | ◇ |
| R. Keith Woods | Option | — | — | — | — | — | — | ◇ |
| R. Keith Woods | PRSU | — | — | — | — | — | — | ◇ |
| Vikas Sinha | PRSU | — | — | — | — | — | — | ◇ |
| Vikas Sinha | Option | — | — | — | — | — | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Akshay Vaishnaw | Option | ◇ | — | ◇ | — |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| R. Keith Woods | Option | ◇ | — | ◇ | — |
| RSU | ◇ | ◇ | — | — | |
| Vikas Sinha | Option | ◇ | — | ◇ | — |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| David Hallal | Option | ◇ | — | ◇ | — |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| PSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Severance and change in control
The terms as written in the agreements.
Akshay Vaishnaw
President of R&D · Employment agreement · citing a 2025 filing
| Severance multiple | ◇ |
| Change-in-control multiple | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
David Hallal
Chief Executive Officer and Chairman · Employment agreement · citing a 2025 filing
| Severance multiple | ◇ |
| Change-in-control multiple | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
R. Keith Woods
Chief Operating Officer · Employment agreement · citing a 2025 filing
| Severance multiple | ◇ |
| Change-in-control multiple | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
Vikas Sinha
Chief Financial Officer · Employment agreement · citing a 2025 filing
| Severance multiple | ◇ |
| Change-in-control multiple | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Jeffrey S. Flier, M.D | ◇ | ◇ | ◇ | — | — | — | ◇ |
Joshua Reed | ◇ | ◇ | ◇ | — | — | — | ◇ |
Katie Peng | ◇ | ◇ | ◇ | — | — | — | ◇ |
Kristina Burow | ◇ | ◇ | ◇ | — | — | — | ◇ |
Michael Gilman, Ph.D | ◇ | ◇ | ◇ | — | — | — | ◇ |
Srinivas Akkaraju, M.D., Ph.D | ◇ | ◇ | ◇ | — | — | — | ◇ |
Richard Brudnick | ◇ | ◇ | ◇ | — | — | — | ◇ |
Akshay Vaishnaw, M.D., Ph.D, David Hallal and Jay Backstrom, M.D., M.P.H served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Agios Pharmaceuticals, Inc. AGIO
- Apellis Pharmaceuticals, Inc. APLS
- Arcus Biosciences, Inc. RCUS
- Arrowhead Pharmaceuticals, Inc. ARWR
- Avidity Biosciences, Inc. RNAM
- Axsome Therapeutics, Inc. AXSM
- Biohaven Ltd. BHVN
- Blueprint Medicines Corporation BPMC
- BridgeBio Pharma, Inc. BBIO
- Crinetics Pharmaceuticals, Inc. CRNX
- Day One Biopharmaceuticals, Inc. DAWN
- Denali Therapeutics Inc. DNLI
- Dyne Therapeutics, Inc. DYN
- Madrigal Pharmaceuticals, Inc. MDGL
- PTC Therapeutics, Inc. PTCT
- Rhythm Pharmaceuticals, Inc. RYTM
- Rocket Pharmaceuticals, Inc. RCKT
- SpringWorks Therapeutics, Inc. SWTX
- Syndax Pharmaceuticals, Inc. SNDX
- Ultragenyx Pharmaceutical Inc. RARE
- Viridian Therapeutics, Inc. VRDN
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | June 4, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | May 22, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | June 27, 2024 | = | ◇ | ◇ | ◇ |
What this page does not include
Everything above is a fact Scholar Rock Holding disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Scholar Rock Holding sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceSay-on-pay responsiveness
Scholar Rock Holding recorded a low support level. The responsiveness analysis covers what the company said it would do, what it did, and how that compares with the companies that recovered their vote.
Responsiveness analysisAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
141 figures on this page: 138 cited to the filing that reported them, 3 calculated from figures it prints.
138 cited to the filing
3 calculated from the filing
Documents cited
- 0001104659-26-070636Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001104659-26-046917DIRECTOR COMPENSATION · Outstanding Equity Awards at 2025 Fiscal Year End Table · Summary Compensation Table · Summary Compensation Table for Fiscal 2025
- 0001558370-25-008134Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001104659-25-033970Summary Compensation Table
- 0001558370-24-009582Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001558370-25-010400EX-10.25 · EX-10.26 · EX-10.27 · EX-10.28
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Scholar Rock Holding executive compensation, FY2024–FY2025.” https://intel.velarion.ai/comp/SRRK (accessed 2026).
Short form: data: Velarion
The Scholar Rock Holding brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
6 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Scholar Rock Holding and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers Scholar Rock Holding discloses
The companies named in SRRK's own disclosed peer group.
Agios Pharmaceuticals, Inc.Apellis Pharmaceuticals, Inc.Arcus Biosciences, Inc.Arrowhead Pharmaceuticals, Inc.Axsome Therapeutics, Inc.Biohaven Ltd.Blueprint Medicines CorporationBridgeBio Pharma, Inc.Crinetics Pharmaceuticals, Inc.Day One Biopharmaceuticals, Inc.Denali Therapeutics Inc.Dyne Therapeutics, Inc.Madrigal Pharmaceuticals, Inc.PTC Therapeutics, Inc.Rhythm Pharmaceuticals, Inc.Rocket Pharmaceuticals, Inc.SpringWorks Therapeutics, Inc.Syndax Pharmaceuticals, Inc.Ultragenyx Pharmaceutical Inc.Viridian Therapeutics, Inc.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}